Cumulative incidence of monotherapy failure in matched samples of sulfonylurea (n=717) versus metformin (n=3585), when followed for up to 5.5 years. Cumulative.

Slides:

Advertisements

Similar presentations

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Advertisements

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Relationship between self-reported adherence to USPSTF/ADA guidelines and evidence from EMR.† The concordance analysis was performed on only 281 surveyed.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Illustration of the causal inference scheme.

Time-course changes in blood glucose (BG; A), C peptide (B), and non-esterified fatty acid (NEFA; C) levels. Time-course changes in blood glucose (BG;

The association between mean annual temperature and diabetes incidence in the USA over the period 1996–2009. The association between mean annual temperature.

Muscle quality (mean±SE, %) of the patients with NDR, NPDR and PDR

(A) Kaplan-Meier renal survival estimates of patients with diabetic nephropathy (DN), non-diabetic renal disease (NDRD) and mixed groups, adjusting for.

Engagement in recommended behaviors to prevent type 2 Diabetes (n=82)

Kaplan–Meier estimates of the incidence of first heart failure hospitalization during follow-up according to the statin category among patients with type.

Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.

Changes in BG levels from 60 min (immediately before the first stair climbing–descending exercise (ST-EX)) to 180 min postmeal. Changes in BG levels from.

Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.

Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.

Estimated HR as a function of absolute change in glycated hemoglobin (HbA1c; from index to measurement 22–26 months after). Estimated HR as a function.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Changes in weight and body mass index (BMI) associated with quality improvement. Changes in weight and body mass index (BMI) associated with quality improvement.

Mathematical modeling of bubble formation in insulin pump cartridges (3 mL solid line, 2 mL dotted line, and 1.8 mL dashed line) and lines during an increase.

Intensity of statin treatment and possible lipid lowering treatment intolerance and/or ineffectiveness issues among patients with type 2 diabetes (aged.

Geographic areas with increased ED visits after Hurricane Sandy by diabetic adults. Geographic areas with increased ED visits after Hurricane Sandy by.

Change in HbA1c and weight compared with baseline variables for the liraglutide group and the placebo group. Change in HbA1c and weight compared with baseline.

Kaplan-Meier plot of incident CVD according to the treatment group over a 4-year period following intensification of diabetes therapy. Kaplan-Meier plot.

Scatterplot showing the association between baseline weight and weight change at 1 year, relative to baseline for each treatment group. Scatterplot showing.

Scatterplot showing the association between change in HbA1c at 1 year and weight change at 1 year, relative to baseline for each treatment group. Scatterplot.

Calibration plot by quintiles of predicted 5-year diabetes risk of the comprehensive German Diabetes Risk Score (GDRS) for prediction of incident diagnosed.

Adjusted annual percentage of quality indicators by prescription

Age-standardized probability of finding undiagnosed diabetes among the US population without diagnosed diabetes aged ≥18 years by survey cycle. Age-standardized.

Daily changes in ED use compared to baseline utilization in October and November 2012 for patients with diabetes in New York City evacuation zone level.

Subgroup analysis of physical activity rates—Asian immigrants versus whites stratified by DM status. Subgroup analysis of physical activity rates—Asian.

Plasma adiponectin levels by race/ethnicity (1A) and gender (1B) among study participants who developed prediabetes/diabetes (Progressors, P) compared.

(A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group). (A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group).

Metabolic syndrome—participants with only three components—expected and observed frequencies by age. Metabolic syndrome—participants with only three components—expected.

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

Inclusion process. Inclusion process. Of 5200 eligible patients, 204 declined participation, 111 had diabetes >400 days before All New Diabetics in Scania.

Correlation between plasma C reactive protein (CRP) and angiopoietin-like protein 4 (ANGPTL4). Correlation between plasma C reactive protein (CRP) and.

Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Kaplan-Meier survival curves for the development.

Change in %A1C over 5 years in response to 12-week intensive lifestyle intervention used in a real-world clinical practice. Change in %A1C over 5 years.

Age-adjusted and sex-adjusted prevalence of diabetes of Asian immigrants and whites in California from 2003 to Age-adjusted and sex-adjusted prevalence.

Whole-body glucose kinetics in C and T2D-O during postabsorptive and clamp states. Whole-body glucose kinetics in C and T2D-O during postabsorptive and.

Association between antibiotic purchases and glycated hemoglobin (HbA1c) values in patients with and without diabetic nephropathy. Association between.

Enrollment of patients.

The results of the influenza vaccination measured by hemagglutination inhibition assay (HIA) among healthy elderly and elderly patients with type 2 diabetes.

The correlation between visceral fat area (VFA) and body mass index (BMI) in patients with type 2 diabetes. The correlation between visceral fat area (VFA)

Relationships between annual antibiotic purchase rates and progression of microalbuminuria in patients with type 1 diabetes. Relationships between annual.

(G) Body mass index (BMI) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (G) Body mass index (BMI) values.

Difference in the prevalence of sarcopenia and its components (low muscle strength and low muscle mass) between NDR, NPDR and PDR. NDR, no diabetic retinopathy;

CONSORT flow diagram for the randomised controlled trial of the iCBT-MDD programme for people with diabetes. iCBT-MDD, internet-based cognitive behaviour.

Mean (95% CI) fasting s-glucose at baseline and 6-month, 12-month, and 24-month follow-up, overall and by sex (A), and by baseline age (B), education (C),

Plasma angiopoietin-like protein 4 (ANGPTL4) in healthy controls (Controls), patients with metabolic syndrome without (MetS−I) and with low-grade inflammation.

Showing significant positive correlation of circulating plasma DPP4 levels with total intra-abdominal adipose tissue volume in patients with T2DM (A) and.

Receiver-operating characteristic curves showing the performance of the diabetes risk score in predicting diabetes in the United Arab Emirates (UAE) citizens.

Categorical A1c distribution within BMI categories, n=414 266 patients with T2D and available A1c data. % values represent percentage of subjects within.

(A) Hemoglobin A1c (HbA1c) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (B) Urinary albumin to creatinine.

Patient flowchart of recruitment and treatment failure and success with glyburide vs. metformin. Patient flowchart of recruitment and treatment failure.

Percentage of weight loss over 5 years in response to 12-week intensive lifestyle intervention in a real-world clinical practice. Percentage of weight.

Oral glucose tolerance testing during hospitalization and at 4 months after infarction. Oral glucose tolerance testing during hospitalization and at 4 months.

Insulin sensitivity (Si-clamp) in obese and non-obese study subjects (A) and cumulative incidence of pre-diabetes/type 2 diabetes in insulin-resistant.

Quarterly hospitalizations of patients diagnosed with primary TB (top) or primary TB and secondary diabetes (bottom) in the USA (NIS, 1998–2011). *Not.

Relationship between week 24 A1C and week 24 BeAM in the exploratory analysis (A), the main analysis (only patients with A1C >7.0% at week 24 were included.

Changes (means±posterior SDs) in HbA1c (A), fasting glucose (B), and body weight (C) by treatment condition based on missing not at random (MNAR) analyses.

Number of events, the crude incidence rate, and the crude and adjusted HR with 95% CI for the association between pioglitazone use and all-cause mortality.

(D) Systolic blood pressure (BP) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. . (D) Systolic blood pressure.

Relationship between time from diagnosis of type 2 diabetes to renal biopsy and the proportion of biopsies with any diabetic nephropathy (DN) and any non-diabetic.

Postprandial glucose, insulin and glucagon-like peptide-1 (GLP-1) levels following carbohydrate-first (CF), carbohydrate-last (CL) and sandwich (S) meal.

Patient disposition and study protocol.

Trends in age-adjusted diagnosed diabetes prevalence and incidence among adults aged 18–79 years, 1980–2017. Trends in age-adjusted diagnosed diabetes.

Prevalence of nephropathy, retinopathy, and neuropathy in subjects achieving all (A) three targets, (B) two targets, (C) one target, and (D) none, and.

Presentation transcript:

Cumulative incidence of monotherapy failure in matched samples of sulfonylurea (n=717) versus metformin (n=3585), when followed for up to 5.5 years. Cumulative incidence of monotherapy failure in matched samples of sulfonylurea (n=717) versus metformin (n=3585), when followed for up to 5.5 years. All patients were on continuous treatment for at least 12 months. (A) All failure; (B) add on; (C) switch; (D) discontinuation. All graphs with log rank test p<0.001, except D with log-rank test non-significant. Nils Ekström et al. BMJ Open Diab Res Care 2015;3:e000059 ©2015 by American Diabetes Association